David Thaler - Insights from other device trials; what can we learn from PFO trials?

Posted on 03-02-17

About this lecture

There are many things to be learned from PFO trails for stroke prevention in other stroke prevention trials, such as the LAA occlusion trials.

Subjects related to this video

Clinical Evidence Patient Information Neurology

Related video's

David Hildick Smith - What’s new: clinical data published and presented since last year

New clinical data for left atrial appendage occlusion therapy, presented & published in 2016. Includes a critical review of the Stroke Prevention section in the 2016 ESC Atrial Fibrillation guidelines.
Clinical Evidence Scientific Meetings

Matthew Price - What’s new: cost effectiveness and health economics

Why might LAA occlusion therapy be cost effective, despite a high procedural cost? This presentation is an overview of the health economics data available for left atrial appendage closure therapy.
Clinical Evidence Scientific Meetings

John Camm, Hans Christop Diener - Debate: Are the new ESC guidelines too strict for LAA Occlusion?

John Camm, UK vs Hans Christoph Diener, DEU    Debate: Are the new ESC guidelines are too strict for Left Atrial Appendage Occlusion? John Camm - Yes, they are too strict. There is a larger group that should benefit from LAA occlusion and it should be stronger recommended too!Hans Christoph Diener - No, the ESC guidelines are right; LAA occlusion Should be limited to OAC contraindicated patients!
Clinical Evidence Indications & Referral Patient Information
+1
To lecture overview